This article first appeared on GuruFocus. More than 630,000 U.S. adults with type 2 diabetes were included in a real-world analysis examining treatment changes involving semaglutide and tirzepatide, Novo Nordisk (NVO) said Tuesday. The analysis covered patients receiving GLP-1 medicines between January 2018 and September 2025. Researchers compared outcomes among people who stayed on 1 mg semaglutide, increased their dose to 2 mg or changed treatment to Eli Lilly (LLY)'s Mounjaro. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart Within one year, around 29% of patients moved to the higher semaglutide dose and about 4% switched to Mounjaro.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.